Acute leukemia type m2 refers to the partially differentiated type of promyelocytic leukemia, and its chromosomal low-risk and high-risk difference lies in the difference in treatment, prognosis and other aspects.
1. Usually, it is necessary to comprehensively determine whether a patient belongs to low-risk or high-risk according to the number of white blood cells, severity of the disease, and chromosomal abnormalities. For example, patients with combined FLT3 gene mutation belong to the high-risk group in terms of prognosis.
2. Compared with the high-risk group, the low-risk group is less prone to disease recurrence and has a relatively high cure rate, and may be able to achieve therapeutic goals through simple chemotherapy. For the high-risk group, a large amount of chemotherapy is needed, and the corresponding drugs may also be needed to effectively prolong the survival period. Specific drugs include cytarabine, Zoerythromycin and so on.
If the patient is diagnosed with acute leukemia type m2, it is recommended to consult a doctor in time, under the guidance of the doctor, improve the relevant examination, clarify the cause of the disease and standardize the treatment.